Background: Cholangiocarcinoma is the second-largest liver cancer, and develops from the biliary epithelium, where it discretely progresses. Unfortunately, many patients miss the opportunity of performing surgery when diagnosed with cholangiocarcinoma, and due to its chemotherapeutic insensitivity, its control has always been considered difficult.

Objective: Here, we present a case of stage 4 cholangiocarcinoma being controlled by the combination of chemotherapy with PD-1 and VEGF/VEGFR2 inhibitors.

Case Presentation: The patient is a 58-year-old male who was diagnosed with a progressed cholangiocarcinoma 2 years ago. From the beginning, metastases were discovered in multiple places, and the patient was unsuccessfully treated with 3 chemotherapy regimens. Therefore, a new therapeutic method was considered, and that involved the testing of a new combination of chemotherapy with PD-1 and VEGF/VEGFR2 inhibitors.

Results: After 6 courses of treatment with this combination, the patient’s lesions became smaller and stable.

Conclusion: Our case highlights the possibility of combining chemotherapy with PD-1 and VEGF/ VEGFR2 inhibitors for the treatment of cholangiocarcinoma patients. This combination may herald new hope for patients who run out of regimens.

背景：胆管癌是第二大肝癌，从胆管上皮发展而来，并在此不连续地进展。不幸的是，许多患者在诊断出患有胆管癌时错过了进行手术的机会，并且由于其对化疗不敏感，其控制一直被认为是困难的。

目的：在这里，我们介绍了一个通过化疗与 PD-1 和 VEGF/VEGFR2 抑制剂联合控制的 4 期胆管癌病例。

病例介绍：患者为 58 岁男性，2 年前被诊断为进展性胆管癌。从一开始，就发现多处转移，患者经过3个化疗方案均未成功。因此，考虑了一种新的治疗方法，包括测试一种新的化疗与 PD-1 和 VEGF/VEGFR2 抑制剂的组合。

结果：经此联合治疗6个疗程后，患者病灶变小、稳定。

结论：我们的案例凸显了将化疗与 PD-1 和 VEGF/VEGFR2 抑制剂联合用于治疗胆管癌患者的可能性。这种组合可能预示着用完治疗方案的患者的新希望。